BBIO vs RDY: stock comparison and AI forecast
Bridgebio Pharma, Inc. (BBIO) and Dr Reddys Laboratories Ltd (RDY) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BBIO Bridgebio Pharma, Inc.
- Market Cap
- $14.47B
- P/E Ratio
- –
- Size
- large-cap
- AI Forecast
RDY Dr Reddys Laboratories Ltd
- Market Cap
- $12.13B
- P/E Ratio
- 16.0x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- BBIO is 1.2 times larger than RDY by market capitalization ($14.47B against $12.13B).
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BBIO | RDY |
|---|---|---|
| Market Cap | $14.47B | $12.13B |
| P/E Ratio | – | 15.96x |
| EPS | $-3.92 | $0.91 |
| Revenue/Share | $4.85 | $4.74 |
| FCF/Share | $-1.90 | $0.28 |
Profitability & Margins
| Metric | BBIO | RDY |
|---|---|---|
| ROA | -26.2% | – |
| ROIC | -30.8% | – |
| Gross Margin | 94.3% | 58.4% |
| Operating Margin | -38.5% | 22.0% |
| Net Margin | -59.8% | – |
| EBT Margin | -67.9% | 23.6% |
| Tax Rate | 0.1% | 25.4% |
Financial Health
| Metric | BBIO | RDY |
|---|---|---|
| Current Ratio | 2.09x | – |
| Quick Ratio | 2.03x | – |
| Interest Coverage | -0.3x | – |
| Working Capital | $1.07B | – |
Cash Flow
| Metric | BBIO | RDY |
|---|---|---|
| Operating Cash Flow | -$369M | $569M |
| Free Cash Flow | -$370M | $237M |
| Capital Spending | -$830K | -$332M |
| FCF Growth YoY | – | 0.0% |
| FCF/Sales | -39.1% | 6.0% |
| CapEx/Sales | 0.1% | 8.4% |
Operational Efficiency
| Metric | BBIO | RDY |
|---|---|---|
| Asset Turnover | 0.44x | – |
| Receivables Turnover | 2.5x | – |
| Inventory Turnover | 0.9x | – |
| Fixed Assets Turnover | 187.5x | – |
| Days Sales Outstanding | 145 days | – |
| Days Inventory | 407 days | – |
| Payables Period | 602 days | – |
| Cash Conversion Cycle | -50 days | – |
Income Statement
| Metric | BBIO | RDY |
|---|---|---|
| Total Revenue | $946M | $3.96B |
| Operating Income | -$364M | $872M |
| Net Income | -$566M | – |
| R&D Expense | $536M | $333M |
| SG&A Expense | $709M | $1.14B |
| Cost of Goods Sold | $54M | $1.65B |
Dividend & Shareholder Information
| Metric | BBIO | RDY |
|---|---|---|
| Shares Outstanding | 195M | 835M |
BBIO vs RDY: stock comparison and AI forecast
Which is bigger, BBIO or RDY?
BBIO is 1.2 times larger than RDY by market capitalization ($14.47B against $12.13B).
Which one does Intratio's AI model rank higher, BBIO or RDY?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.